We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
SYGNIS AG Launches TruePrime™ Apoptotic Cell Free DNA Amplification Kit for the Liquid Biopsy Market
Product News

SYGNIS AG Launches TruePrime™ Apoptotic Cell Free DNA Amplification Kit for the Liquid Biopsy Market

SYGNIS AG Launches TruePrime™ Apoptotic Cell Free DNA Amplification Kit for the Liquid Biopsy Market
Product News

SYGNIS AG Launches TruePrime™ Apoptotic Cell Free DNA Amplification Kit for the Liquid Biopsy Market


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "SYGNIS AG Launches TruePrime™ Apoptotic Cell Free DNA Amplification Kit for the Liquid Biopsy Market"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SYGNIS AG the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, has announced the launch of its TruePrime™ apoptotic cell free DNA amplification kit, under the Expedeon brand. The kit enables accurate DNA amplification using cell free DNA (cfDNA) obtained from plasma, serum, urine, cerebrospinal fluid (CSF), or many other bodily fluids.

Dr. Heikki Lanckriet, CEO and CSO of SYGNIS AG, commented: “This new TruePrime™ apoptotic cell free DNA amplification kit launch comes at a very important period in the growing liquid biopsy market, as applications for the liquid biopsy market will become an important growth driver for Sygnis. The technology contains the latest advances in amplification techniques, sensitivity and simplicity. The addition of this kit to our portfolio supports our contribution to the global effort to discover the genetic cancer markers, which are vital for successful treatments and cures. Additionally, we are further strengthening our IP position around this technology and process.”

The TruePrime™ apoptotic cell free DNA amplification kit uses a novel multiple displacement amplification method to overcome the common limitations with the analysis of bodily fluid for cell free DNA analysis. By exponentially amplifying cell-free DNA derived from apoptosis, the cell-death mechanism, these TruePrimeTM kits provide users with excellent sensitivity, error-free amplification in high yields and a streamlined workflow for reduced hands-on time.

The new technology expands the Company’s range of TruePrime™ kits, further strengthening its offering within the growing liquid biopsy market, which is set to increase at a CAGR of 23% by 2022. Kits and consumables are the leading sub-segment to the global liquid biopsy market value. Key factors driving this market include the demand for the detection and monitoring of cancer, which is increasing alongside disease prevalence. The new technology has potential to meet this demand through its use in Next Generation Sequencing (NGS)-based clinical diagnostics.
Advertisement